We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Dual Diagnosis (Psychosis and Cannabismisuse): Comparison of Specialized Treatment Versus Unspecified Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00783185
Recruitment Status : Completed
First Posted : October 31, 2008
Last Update Posted : January 12, 2010
Sponsor:
Information provided by:

Study Description
Brief Summary:

Intention of the study is to examine, if the symptomatology of dual diagnosis patients is less severe after a special indication training for reduction of cannabis consumption in comparison to unspecified trainings.

Point of interest is psychopathology and consumerism.


Condition or disease Intervention/treatment Phase
Psychotic Disorders Marijuana Abuse Intervention Behavioral: Cannabis-Consumption-Reduction-Training Behavioral: Social competence Training Phase 1

Detailed Description:

Dual diagnosis patients (psychosis and cannabis abuse) account for more clinical admissions than single diagnosis patients.

Cannabis misuse is a known risk factor for recurrence of psychosis.

A specified intervention on the basis of a manual for schizophrenic substance abusers is administered to inpatients in a specialized unit for young schizophrenic patients in a psychiatric hospital.

The control group, same indication (psychotic disorder and cannabis misuse) receives social competence training (specified for schizophrenic patients as well).

Admission to groups is randomly.


Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Dual Diagnosis Psychosis and Substance Abuse: Short- and Middle-term Changes in Symptomatology After Visiting a Group Education Programme to Reduce Consumption of Cannabis
Study Start Date : January 2006
Primary Completion Date : June 2009
Study Completion Date : January 2010

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: ACT
Anti-Cannabis-Consumption-Training
Behavioral: Cannabis-Consumption-Reduction-Training
8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
Active Comparator: CG
Control group
Behavioral: Social competence Training
8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences


Outcome Measures

Primary Outcome Measures :
  1. PANSS Positive and Negative Symptom Scale [ Time Frame: post intervention, six months follow-up ]

Secondary Outcome Measures :
  1. Urinstatus for cannabinoids [ Time Frame: weekly during and post intervention, follow-up ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Clinical diagnosis of schizophrenia and disorders with psychotic features
  • Misuse of cannabis during 12 months preceding admission to hospital

Exclusion Criteria:

  • Not able to attend training twice a week for 45 minutes (concentration, attention, psychotic symptoms, agitation)
  • Discharge from hospital before completion of training
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00783185


Locations
Germany
University of Konstanz
Konstanz, Baden-Württemberg, Germany, 78462
Sponsors and Collaborators
University of Konstanz
Investigators
Principal Investigator: Hans Watzl, Dr. University of Konstanz
More Information

Responsible Party: Hans Watzl, Dr., University of Konstanz
ClinicalTrials.gov Identifier: NCT00783185     History of Changes
Other Study ID Numbers: CRET
First Posted: October 31, 2008    Key Record Dates
Last Update Posted: January 12, 2010
Last Verified: October 2008

Keywords provided by University of Konstanz:
psychotic disorders
cannabis
intervention

Additional relevant MeSH terms:
Mental Disorders
Psychotic Disorders
Marijuana Abuse
Schizophrenia Spectrum and Other Psychotic Disorders
Substance-Related Disorders
Chemically-Induced Disorders